New Mexico State University researchers collaborating with the New Mexico Department of Health recently published a paper that shows there is widespread resistance to insecticides in one type of mosquito found in southern New Mexico â Aedes aegypti, the yellow fever mosquito.
Researchers say insecticide resistance is a serious problem, which evolves in insect populations when they are repeatedly exposed to the same type of insecticide or insecticides. This resistance can undermine public health efforts. This study characterized for the first time insecticide resistance of the yellow fever mosquito across its range in New Mexico.
“With climate change, New Mexico will increasingly be seeing mosquito-borne disease,” said NMDOH state epidemiologist Michael Landen. “This paper provides an important warning of how insecticide resistance in the state will complicate our ability to control these diseases and that we need to work on alternatives.”
The article, which outlines widespread insecticide resistance of the state’s yellow fever mosquito population, was published Feb. 22 in PLos One, a peer-reviewed open access scientific journal. It was authored by a number of researchers in the NMSU Departments of Biology and Geography along with the NMDOH.
The research was part of the SouthWest Aedes Research and Mapping project funded by NMDOH with biology professors Kathryn Hanley, Jiannong Xu and Immo Hansen along with geography professor Michaela Buenemann as principal investigators. As part of the SWARM project, yellow fever mosquitoes were collected from around the state and taken to Hansen’s Molecular Vector Physiology Lab at NMSU where bottle tests were conducted.
“It’s very easy, you take a bottle, put a certain amount of insecticide in there and let it dry,” said Hansen. “Then you put mosquitoes inside and record the time it takes them to die. A resistant strain takes maybe an hour until all of them are dead. If you have a susceptible strain they die in the first 5 minutes.”
In addition to trapping and testing mosquitoes, the study also elicited data from some vector control entities in counties and cities across New Mexico about pesticides used in 2017 for mosquito control as well as methods used over the previous five years.
Overall, results of the study demonstrate widespread resistance to pyrethroid insecticides.The majority of the mosquito populations analyzed were resistant to the permethrin and deltamethrin, with one exception ââAlamogordo, a city that did not use pyrethroids or chemical pesticides but instead used the bacterial larvicide Vectobac.
“In Alamogordo we did not find resistence in our study, you can see they are not resistant at all, which is good news for vector control,” Hansen said. “In Roswell and Deming, the mosquitoes we tested were highly insecticide-resistant. In other places we saw mixed populations. To address this issue of insecticide resistance, we suggest vector control have a management plan to rotate periodically from one active ingredient to another and consider exploring alternative approaches to mosquito control that do not involve insecticides.”
Source: New Mexico State University (NMSU)
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
Managing Multimorbidity and Polypharmacy in HIV: Insights From Michelle S. Cespedes, MD, MS
November 20th 2024Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.
Longhorn Vaccines and Diagnostics to Showcase Breakthrough Vaccine Data at IDWeek 2024
November 19th 2024Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.